Autosomal Dominant Polycystic Kidney Disease Treatments

Find Autosomal Dominant Polycystic Kidney Disease Treatments

Generic Name

Tolvaptan

Brand Names

Jynarque, Samsca

FDA approval date: May 19, 2009

Classification: Vasopressin V2 Receptor Antagonist

Form: Tablet, Kit

What is Jynarque (Tolvaptan)?

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease . JYNARQUE is a selective vasopressin V 2 -receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Enrollment Status: Recruiting

Publish Date: June 15, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.

The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.

Enrollment Status: Recruiting

Publish Date: April 30, 2026

Summary: The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide real-world data ...

A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Who is this study for: Patients with Autosomal Recessive Polycystic Kidney (ARPKD)

Enrollment Status: Recruiting

Publish Date: February 17, 2026

Intervention Type: Drug

Study Drug: Tolvaptan

Study Phase: Phase 3

Summary: To evaluate the safety of tolvaptan in pediatric subjects with ARPKD

View All Clinical Trials